Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Shoichi KimuraDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0002-1123-6815
Satoshi IwanoInstitute for Tenure Track Promotion, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0003-3757-1504
Takahiro AkiokaDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Takahiro KuchimaruCenter for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan.
Makiko KawaguchiSection of Oncopathology and Morphological Pathology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0001-8210-5460
Tsuyoshi FukushimaSection of Oncopathology and Morphological Pathology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0002-9350-777X
Yuichiro SatoSection of Oncopathology and Morphological Pathology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Hiroaki KataokaOrganization for Promotion of Research and Industry Academic Regional Collaboration, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0001-9948-0451
Toshiyuki KamotoDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Shoichiro MukaiDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Atsuro SawadaDepartment of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Funding
Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture and Japan Society for Promotion of Science, Japan JP22K09506, JP23K08737
6 · The paper itself
Abstract
The liver is the most lethal metastatic site in castration-resistant prostate cancer (CRPC). Overexpression of MET protein has been reported in CRPC, and
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC. · full record | OpenQuestion